Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Quidel Corporation    QDEL

QUIDEL CORPORATION

(QDEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Quidel Corporation
Quidel Corp. is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: rapid immunoassays, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of many diseases and medical conditions, including infectious diseases, cardiovascular diseases and conditions, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Amplivue, Lyra and Thyretain.

Number of employees : 1 250 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Cardiac Immunoassay266.5251%266.5149.8% -0.01%
Rapid Immunoassay183.1635.1%191.7435.8% +4.68%
Specialized Diagnostic Solutions53.2410.2%54.9310.3% +3.17%
Molecular Diagnostic Solutions19.363.7%21.724.1% +12.18%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States354.9068%358.3867% +0.98%
Foreign167.3932%176.5133% +5.45%
Managers
NameAgeSinceTitle
Douglas Bryant612009President, Chief Executive Officer & Director
Kenneth Buechler652015Chairman
Robert Bujarski512020Chief Operating Officer
Randall J. Steward642011Chief Financial Officer
Werner Kroll, Dr.622014Senior Vice President-Research & Development
Karen S. Gibson562019SVP-Information Systems & Business Transformation
Mary Lake Polan, Dr.751993Independent Director
Kenneth J. Widder, Dr.662014Independent Director
Charles P. Slacik652015Independent Director
Matthew William Strobeck, Dr.462018Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 42,067,646 37,096,890 88.2% 0 0.0% 88.2%
Shareholders
NameEquities%
Jack Schuler 4,273,512 10.2%
T. Rowe Price Associates, Inc. (Investment Management) 4,236,715 10.1%
The Vanguard Group, Inc. 3,518,105 8.39%
Brown Capital Management LLC 2,305,481 5.50%
Oracle Investment Management, Inc. 1,816,094 4.33%
Fred Alger Management LLC 1,609,095 3.84%
Longwood Investment Advisors, Inc. 1,241,900 2.96%
BlackRock Fund Advisors 1,183,856 2.82%
WHV Investments, Inc. 1,162,073 2.77%
Peregrine Capital Management LLC 1,021,500 2.44%
Sector Advanced Medical Equipment & Technology - NEC